Search results
Results from the WOW.Com Content Network
Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and ... Drugs in the company's pipeline includes medications designed to ...
Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.
Arena Pharmaceuticals (NAS: ARNA) is revving up for the launch of its obesity drug, Belviq. The drug was the first obesity drug approved earlier this year but got held back by DEA scheduling while ...
Giant pharmaceutical company Pfizer agreed earlier today to acquire Arena Pharmaceuticals in a deal worth roughly $6.7 billion.
Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the third quarter of 2019 while revenues beat estimates.
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
Let's look at Arena Pharmaceuticals (NAS: ARNA) today and. When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons, and decide whether it's ...